美国癌症协会2026年结直肠癌筛查指南更新
美国癌症协会(ACS)2026年更新结直肠癌筛查指南,基于系统性证据回顾 reaffirm 平均风险成人45岁起筛查至75岁(预期寿命>10年),并推荐新一代粪便检测(mt-sDNA、mt-sRNA)为 preferred 选项(每3年),血液检测仅用于拒绝或不完成 preferred 筛查者。
要点
- 平均风险成人45岁开始筛查,持续至75岁(预期寿命>10年)。
- 首选粪便筛查包括新一代mt-sDNA、mt-sRNA及高敏FIT/gFOBT,间隔3年。
- 血液cfDNA检测灵敏度较低,仅推荐给拒绝或不完成首选筛查者。
核心结论
- ACS reaffirm 平均风险成人45岁起始筛查至75岁(预期寿命>10年)。
- 新一代粪便检测(mt-sDNA、mt-sRNA)作为 preferred 粪便筛查选项推荐。
- 血液检测灵敏度低于粪便检测,仅用于拒绝或不完成 preferred 筛查者。
研究设计与样本
- ACS指南制定组委托开展针对性系统性证据回顾,评估诊断性能及建模研究对发病率死亡率的影响。
主要发现
- mt-sRNA和下一代mt-sDNA对CRC灵敏度高,对晚期癌前病变灵敏度中等。
- 血液检测对晚期癌前病变和I期癌灵敏度低于既有粪便检测。
- 建模研究预测血液检测降低CRC发病率和死亡率的效果较差。
关键数值与推荐
- 平均风险成人45岁开始筛查,持续至75岁(预期寿命>10年)。
- 首选粪便筛查:下一代mt-sDNA、mt-sRNA、高敏FIT、高敏gFOBT,间隔3年。
- 血液检测仅推荐给拒绝或不完成 preferred 筛查的个体。
- 任何非结肠镜筛查阳性需6个月内完成结肠镜随访。
临床怎么用
- 提供多种推荐筛查选项以支持患者知情选择,提高参与率。
- 优先推荐粪便检测(mt-sDNA、mt-sRNA、FIT/gFOBT)或结肠镜。
- 血液检测不作为首选,仅用于拒绝或不完成首选筛查者。
- 确保阳性结果者在6个月内完成结肠镜随访。
局限性
- 需持续评估依从性、真实世界实施和临床结局以指导未来更新。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Colorectal cancer (CRC) is a leading cause of cancer incidence and mortality in the United States, with rates recently increasing among adults younger than 65 years. In 2018, the American Cancer Society (ACS) lowered the recommended age to initiate screening for average-risk adults to age 45 years. Since then, new molecular-based screening tests-a multitarget stool RNA test (mt-sRNA), a next-generation mt-sDNA test, and a blood-based cell-free DNA assay-have received regulatory approval for CRC screening. For this update, the ACS Guideline Development Group commissioned a targeted, systematic evidence review evaluating diagnostic performance and published modeling studies to judge the potential impact of these tests on CRC incidence and mortality. The ACS reaffirms the recommendation that average-risk adults should initiate CRC screening at age 45 years and continue through age 75 years for those with a life expectancy greater than 10 years. Consistent with prior guidelines, the ACS emphasizes that offering multiple, recommended screening options supports informed patient choice and may improve participation, because the most effective screening test is the one that the patient completes. The next-generation mt-sDNA test, which is an updated version of an already recommended mt-sDNA test, and the mt-sRNA test demonstrated high sensitivity for CRC and moderate sensitivity for advanced precancerous lesions and are recommended, along with annual high-sensitivity fecal immunochemical and high-sensitivity guaiac-based fecal occult blood tests, as preferred stool-based screening options at 3-year intervals. Compared with established stool-based tests, blood-based tests demonstrated lower sensitivity for both advanced precancerous lesions and stage I cancers, with modeling studies predicting less effectiveness in reducing CRC incidence and mortality. At this time, blood-based tests should be recommended only to individuals who decline or do not complete preferred screening tests. Ongoing evaluation of adherence, real-world implementation, and clinical outcomes will inform future updates for these new tests. For screening to be effective, a positive result on any noncolonoscopy screening test requires timely follow-up with colonoscopy, preferably within 6 months, to complete the screening process.
引用
- Wolf AMD, Hoffman RM, Walter LC, et al. Colorectal cancer screening: An update to the American Cancer Society guideline, 2026. CA Cancer J Clin. 2026. PMID: 42200680. doi:10.3322/caac.70083
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。